The incoming changes to hemp classification in the US are already facing major issues, with the Government’s own Congressional Research Service (CRS) stating that it remains ‘unclear’ how it will be enforced in practice.
With a year to go before the new rules are enacted, set to have major implications for both the industrial hemp and intoxicating hemp industries, advocates are warning that the sweeping restrictions will decimate the US thriving seeds and genetics market.
The report notes that both the Food and Drug Administration and Drug Enforcement Administration ‘may lack the resources to broadly enforce the laws prohibiting intoxicating hemp products on the market,’ leading to questions over whether the ban will mirror the federal government’s hands-off approach to state-legal marijuana.
In a CRS analysis published earlier this month (December 03), the agency highlights potential parallels to the state enforcement of cannabis, noting that despite cannabis remaining federally illegal as a Schedule I controlled substance, ‘the federal response has largely been to allow states to implement their own marijuana laws despite the fact that state-regulated activities may violate the Controlled Substances Act.’
If intoxicating hemp products persist after November 13, 2026, when the new definition takes effect, they ‘could be subject to the same criminal and collateral issues as marijuana,’ the report noted.
This would include potential banking restrictions, interstate commerce limitations, and exposure to federal prosecution, though the likelihood of enforcement remains unclear.
The law requires FDA to publish lists of naturally occurring cannabinoids, THC-class cannabinoids, and cannabinoids with THC-like effects within 90 days of enactment, a deadline falling in mid-February 2026. The agency must also define the term ‘container’ for purposes of the 0.4 milligram per-container limit.
However, the CRS says it ‘remains to be seen’ whether FDA will pursue enforcement actions beyond these administrative requirements.
The report highlights that both the Food and Drug Administration and Drug Enforcement Administration ‘may lack the resources to broadly enforce the laws prohibiting intoxicating hemp products on the market, particularly given the scale of the industry and the complexity of distinguishing compliant from non-compliant products.
The nonpartisan research agency, which serves as shared staff to congressional committees and members of Congress, added that the FDA and DEA, ‘in coordination with the Department of Justice, have a range of civil and criminal remedies they may use in efforts to exercise control over these activities,’ but stopped short of predicting which enforcement mechanisms might be deployed.
Furthermore, it suggests Congress ‘may choose to exercise oversight over federal enforcement priorities regarding state-regulated cannabis activities, suggesting potential political pressure on how aggressively agencies pursue violations.
December 5, 2025 No Comments
November 25, 2025 No Comments
November 20, 2025 No Comments
An underreported aspect of the legislation explicitly restricts ‘any viable seeds from a Cannabis Sativa L. plant that exceeds a total tetrahydrocannabinol concentration (including THCA) of 0.3% in the plant on a dry weight basis.’
This seed restriction has drawn sharp criticism from industry figures who argue it will destroy the US cannabis genetics market by creating an impossible compliance standard.
“All [seeds] look the same until you wait a minimum of three months to see what they really are,” Sergio Martínez, chief executive of Spain-based Blimburn Seeds, told the Guardian. “There is a misunderstanding about strains, even hemp plants registered in Europe as less than 0.3% THC if you are a good grower, you could get these numbers up.”
The restriction effectively bans seeds based on what plants they might produce rather than their own THC content, creating a regulatory challenge since seeds contain negligible THC themselves.
Jamie Pearson, president of the New Holland Group, warned that only large, well-resourced companies will be able to comply with certification requirements, pushing cannabis genetics underground.
“These genetics are really the heart and soul of the cannabis industry,” Pearson told the Guardian.
“It’s going to be a handful of the really large companies that have those right licenses. All those genetics, the good wine will go underground, and you’re just going to get Ernest and Julio Gallo, rather than all the varietals that we can get at our local wine store.”
The seed ban poses particular risks for medical cannabis patients who grow their own plants for specific therapeutic purposes. Legal seed markets have allowed companies to cultivate strains targeting conditions including epilepsy, chronic pain, and chemotherapy-induced nausea.
Since the 2018 Farm Bill, seeds have been treated as hemp products because they contain less than 0.3% delta-9 THC. Most states allowed seeds to be purchased and shipped without triggering drug laws, and companies could sell and import seeds without special permits.
The post Federal Agencies ‘May Lack Resources’ to Enforce US Hemp Ban, Congressional Researchers Warn appeared first on Business of Cannabis.
Continue reading...
With a year to go before the new rules are enacted, set to have major implications for both the industrial hemp and intoxicating hemp industries, advocates are warning that the sweeping restrictions will decimate the US thriving seeds and genetics market.
The report notes that both the Food and Drug Administration and Drug Enforcement Administration ‘may lack the resources to broadly enforce the laws prohibiting intoxicating hemp products on the market,’ leading to questions over whether the ban will mirror the federal government’s hands-off approach to state-legal marijuana.
CRS raises critical issues with legislation
In a CRS analysis published earlier this month (December 03), the agency highlights potential parallels to the state enforcement of cannabis, noting that despite cannabis remaining federally illegal as a Schedule I controlled substance, ‘the federal response has largely been to allow states to implement their own marijuana laws despite the fact that state-regulated activities may violate the Controlled Substances Act.’
If intoxicating hemp products persist after November 13, 2026, when the new definition takes effect, they ‘could be subject to the same criminal and collateral issues as marijuana,’ the report noted.
This would include potential banking restrictions, interstate commerce limitations, and exposure to federal prosecution, though the likelihood of enforcement remains unclear.
The law requires FDA to publish lists of naturally occurring cannabinoids, THC-class cannabinoids, and cannabinoids with THC-like effects within 90 days of enactment, a deadline falling in mid-February 2026. The agency must also define the term ‘container’ for purposes of the 0.4 milligram per-container limit.
However, the CRS says it ‘remains to be seen’ whether FDA will pursue enforcement actions beyond these administrative requirements.
The report highlights that both the Food and Drug Administration and Drug Enforcement Administration ‘may lack the resources to broadly enforce the laws prohibiting intoxicating hemp products on the market, particularly given the scale of the industry and the complexity of distinguishing compliant from non-compliant products.
The nonpartisan research agency, which serves as shared staff to congressional committees and members of Congress, added that the FDA and DEA, ‘in coordination with the Department of Justice, have a range of civil and criminal remedies they may use in efforts to exercise control over these activities,’ but stopped short of predicting which enforcement mechanisms might be deployed.
Furthermore, it suggests Congress ‘may choose to exercise oversight over federal enforcement priorities regarding state-regulated cannabis activities, suggesting potential political pressure on how aggressively agencies pursue violations.
Medicare CBD Coverage Proposed, But Federal Ban Threatens Entire Industry
Read More »December 5, 2025 No Comments
UK Court Throws Out CBD Case Over Improper Testing, but Operators ‘More Vulnerable Than Ever’
Read More »November 25, 2025 No Comments
EU ‘Intoxicating Hemp’ Review Highlights Major Knowledge Gaps Behind Blanket Bans
Read More »November 20, 2025 No Comments
Seed ban threatens the genetics market
An underreported aspect of the legislation explicitly restricts ‘any viable seeds from a Cannabis Sativa L. plant that exceeds a total tetrahydrocannabinol concentration (including THCA) of 0.3% in the plant on a dry weight basis.’
This seed restriction has drawn sharp criticism from industry figures who argue it will destroy the US cannabis genetics market by creating an impossible compliance standard.
“All [seeds] look the same until you wait a minimum of three months to see what they really are,” Sergio Martínez, chief executive of Spain-based Blimburn Seeds, told the Guardian. “There is a misunderstanding about strains, even hemp plants registered in Europe as less than 0.3% THC if you are a good grower, you could get these numbers up.”
The restriction effectively bans seeds based on what plants they might produce rather than their own THC content, creating a regulatory challenge since seeds contain negligible THC themselves.
Jamie Pearson, president of the New Holland Group, warned that only large, well-resourced companies will be able to comply with certification requirements, pushing cannabis genetics underground.
“These genetics are really the heart and soul of the cannabis industry,” Pearson told the Guardian.
“It’s going to be a handful of the really large companies that have those right licenses. All those genetics, the good wine will go underground, and you’re just going to get Ernest and Julio Gallo, rather than all the varietals that we can get at our local wine store.”
The seed ban poses particular risks for medical cannabis patients who grow their own plants for specific therapeutic purposes. Legal seed markets have allowed companies to cultivate strains targeting conditions including epilepsy, chronic pain, and chemotherapy-induced nausea.
Since the 2018 Farm Bill, seeds have been treated as hemp products because they contain less than 0.3% delta-9 THC. Most states allowed seeds to be purchased and shipped without triggering drug laws, and companies could sell and import seeds without special permits.
The post Federal Agencies ‘May Lack Resources’ to Enforce US Hemp Ban, Congressional Researchers Warn appeared first on Business of Cannabis.
Continue reading...
